researc-dev1

Research & Development

Sanofi Pasteur MSD is proud to potentially be able to draw from two world leading pipelines for its vaccine development and delivery.

  • Sanofi Pasteur MSD Pipeline

    Phase III Registration New Vaccines

    Quadrivalent Influenza Vaccine

    Pediatric Hexavalent Vaccine

    9 valent HPV vaccine (V503)

    Hexyon

    Zostavax

    ProQuad

  • Sanofi Pasteur R&D Pipeline – 11 vaccines in development1

    Phase I Phase II Phase III Registration

    Streptococcus pneumoniae

    Meningitis & pneumonia vaccine

    Herpes Simplex Virus Type 2

    HSV-2 vaccine

    Meningitis ACYW conj

    2nd generation meningococcal conjugate infant vaccine

    Rage VRVg

    Purified vero rabies vaccine

    Tuberculosis

    Recombinant subunit vaccine

    Vaxigrip® QIV IM

    Quadrivalent inactivated influenza vaccine

    Clostridium difficile

    Toxoid vaccine

    Rotavirus

    Live attenuated tetravalent Rotavirus oral vaccine

    Quadracel®

    Diphtheria, tetanus pertussis & polio vaccine; 4-6y of age

    Dengue

    Mild to severe dengue fever

    DTP-HepB-Polio-Hib (PR5I)

    Pediatric hexavalent vaccine

    1 source : Sanofi Pasteur Pipeline, February 25 2015, phase I to registration

  • Merck R&D Pipeline1

    Phase II Phase III Under Review

    Pneumoconjugate Vaccine,

    V114

    Pediatric Hexavalent Combination Vaccine,

    V419

    Herpes Zoster Inactivated VZV Vaccine,

    V212

    HPV-Related Cancers

    HPV Vaccine (9 Valent)
    V503 (US)

     

    1 : Source : Merck Pipeline as of April 30, 2014

  • Sanofi Pasteur MSD pipelinespmsdpipeline
  • Sanofi Pasteur R&D Portfoliosanofipasteurpipeline
  • Merck R&D Portfoliomerckpipeline